There are 3161 resources available
The past, present, and future for melanoma therapy
Presenter: Michael Postow
Session: Bristol Myers Squibb - A decade of anti—PD-1—based therapies for melanoma: looking beyond the curves
Resources:
Webcast
The adjuvant puzzle: how do we pick the right patient?
Presenter: Jens Bedke
Session: Ipsen - Kidney cancer puzzles – from insights to progress
Resources:
Webcast
Biological insights in the endocrine and CDK4/6 pathways of cellular signal transduction and mechanisms of primary/acquired resistance in HR(+)/HER2(-) breast cancer
Presenter: Elgene Lim
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Slides
Webcast
aRCC 1L treatment selection
Presenter: Brian Rini
Session: Eisai Inc. - Evolving Treatment Sequence for Renal Cell Carcinoma
Resources:
Webcast
2024 treatment in focus: immuno-oncology for the neoadjuvant/perioperative setting
Presenter: Christoph Hoeller
Session: Bristol Myers Squibb - A decade of anti—PD-1—based therapies for melanoma: looking beyond the curves
Resources:
Webcast
How can you select the best 1L option for your patient?
Presenter: Sumanta Pal, Laurence Albiges
Session: Ipsen - Kidney cancer puzzles – from insights to progress
Resources:
Webcast
Presentation of a clinical case: State of the art management of patients with HR(+)/HER2(-) advanced breast cancer progressing after aromatase inhibitor+CDK4/6-inhibitor therapy
Presenter: Cristina Saura Manich
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Slides
Webcast
Managing response to IO-TKI combinations in 1L RCC
Presenter: Viktor Gruenwald
Session: Eisai Inc. - Evolving Treatment Sequence for Renal Cell Carcinoma
Resources:
Webcast
How can we simplify sequencing?
Presenter: Guillermo Antonio De Velasco Oria
Session: Ipsen - Kidney cancer puzzles – from insights to progress
Resources:
Webcast
HR(+)/HER2(-) advanced breast cancer: How can biology inform us on optimising the precision therapeutic strategies in 1L and 2L post progression after endocrine+CDK4/6i?
Presenter: Philippe Aftimos
Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition
Resources:
Slides
Webcast